ISPOR - PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS?

Full Text

PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS?

Abstract

Authors

X. Radu R. Campbell M. Martin

Back to Volume 21, Supplemental S3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now